All In MedTech

Device Trial Radar · NCT03614260

The RADIANCE II Pivotal Study: A Study of the ReCor Medical Paradise System in Stage II Hypertension

Last checked: Nov 20, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingTitle says "pivotal". Randomized with 224 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

224

Actual

Start

Dec 14, 2018

Primary completion

Dec 21, 2022

Study completion Jul 2029

Sponsor

Lead sponsor
ReCor Medical, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Aug 3, 2018

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of the RADIANCE II Pivotal study is to demonstrate the effectiveness and safety of the Paradise System in subjects with Stage 2 hypertension on 0-2 medications at the time of consent. Prior to randomization, subjects will be hypertensive in the absence of hypertension medication.

Conditions

  • Hypertension
  • Vascular Diseases
  • Cardiovascular Diseases

Interventions

  • Paradise Renal Denervation SystemDevice

    Following renal angiogram according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.

  • Renal AngiogramProcedure

    Following renal angiogram to standard procedures, subjects remain blinded and renal angiogram is considered the sham procedure.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Average Daytime Ambulatory Systolic BPTime frame: From baseline to 2 months post-procedure
  2. Percentage of Participants With Major Adverse Events (MAE)Time frame: From baseline to 30 days post-procedure

Locations

47 sites in 8 countries. Site status is shown where the registry gives one.

  • Cardiology PC

    Birmingham, Alabama

  • Cedars Sinai Medical Center

    Los Angeles, California

  • Bridgeport Hospital

    Bridgeport, Connecticut

44 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.